The clinical evaluation of prazosin, a new antihypertensive agent.
The hemodynamic and therapeutic profiles of prazosin have been delineated in a comprehensive clinical program involving more than 1,000 patients. Efficacy was established in double-blind placebo-controlled studies and open, noncomparative long-term studies and comparisons with standard antihypertensive agents. The efficacy and safety of prazosin make it particularly suitable for initiation and maintenance of long-term outpatient therapy for hypertension.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008750:Methyldopa / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010919:Placebos; D011674:Pulse / Q000187:drug effects; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D010879:Piperazines; D010919:Placebos; D011799:Quinazolines; D049993:Sodium Chloride Symporter Inhibitors; D008750:Methyldopa